TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02883660

Intervention type: GENETIC
Intervention: Genocept Assay
Description: battery of pharmacogenetic tests relevant to psychiatry

Intervention type: GENETIC
Intervention: Genocept Assay
Description: battery of pharmacogenetic tests relevant to psychiatry
Study: NCT04018924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)
Description: Debridement and Dressing or compressive dressing if needed
Study: NCT00960024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support-vocational rehabilitation
Description: Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
Study: NCT00389376

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 140 mg every 8 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 280 mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 280 mg single dose + every 8 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 560 mg single dose + every 8 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 560 mg single dose + every 8 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 280 mg every 8 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 700 mg single dose + every 8 hours
Study: NCT02000024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Description: The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers
Description: The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National Diabetes Education Program
Study: NCT02046837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised 1:1 exercise
Description: The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Description: The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
Study: NCT04575545

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology test for COVID-19
Description: ELISA test

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology test for COVID-19
Description: ELISA test
Study: NCT01557101

Intervention type: PROCEDURE
Group type: OTHER
Intervention: COLON CAPSULE ENDOSCOPY ADHERENCE
Description: An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: OPTICAL COLONOSCOPY ADHERENCE
Description: An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
Study: NCT05329753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile health application
Description: Health intervention through a smartphone application that favors the process of learning
Study: NCT02151786

Intervention type: DRUG
Intervention: Lansoprazole
Description: Lansoprazole intravenous 30 mg
Study: NCT02178319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgical procedure
Description: open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgical procedure
Description: laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
Study: NCT01758562

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Caphosol
Study: NCT04115839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets will be administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets will be administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets will be administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets will be administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food.
Study: NCT00187577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost (Xalatan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost (Lumigan)
Description: Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application of latanoprost solution to eyelid
Description: Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
Study: NCT03744091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P1
Description: 10 mg or 20 mg of THC:THCa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P1
Description: 10 mg or 20 mg of THC:THCa
Study: NCT00602797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV
Study: NCT04736407

Intervention type: OTHER
Intervention: Observational sampling of CSF timed around routine clinical repositioning, or not
Description: no true intervention

Intervention type: OTHER
Intervention: Observational sampling of CSF timed around routine clinical repositioning, or not
Description: no true intervention
Study: NCT03588039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered
Study: NCT04194398

Intervention type: DEVICE
Intervention: OCS Lung System
Description: Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.
Study: NCT03523897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot Assisted Total Knee Replacement
Description: A robotic-assisted surgical procedure to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Total Knee Replacement
Description: A surgical procedure using mechanical guides to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
Study: NCT01277913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1000 IU once daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 500 IU once daily for 12 months
Study: NCT03180242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EG12014
Description: EG12014, single-dose IV infusion over 90 min at 6 mg/kg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Herceptin
Description: EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced Herceptin
Description: US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
Study: NCT02988219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl
Description: Local anesthetic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter ECG monitor
Description: 3-chanel, CM5 leads

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holter ECG monitor
Description: 3-chanel, CM5 leads

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open kidney cancer surgery
Description: Lateral position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open kidney cancer surgery
Description: Lateral position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Anaesthesia
Study: NCT03636113

Intervention type: DEVICE
Intervention: Clarity RMS Electronic Sensor
Description: The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
Study: NCT01521572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate
Description: bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
Study: NCT01115088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspartame
Description: The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stevia
Description: The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
Study: NCT02137707

Intervention type: DRUG
Intervention: Gilenya
Description: All patients will receive Gilenya
Study: NCT06081699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral
Study: NCT00803595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8958
Description: CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
Study: NCT06081699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral
Study: NCT00803595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8958
Description: CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
Study: NCT00960024

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocational rehabilitation available
Description: The participants are offered vocational rehabilitation available at site
Study: NCT05537194

Intervention type: DRUG
Intervention: dihydropyridine calcium channel inhibitors use
Description: administration of dihydropyridine calcium channel inhibitors
Study: NCT06081699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNP-2198 Placebo
Description: The placebo for TNP-2198 active drug
Study: NCT03200808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixed methylene blue compound injection
Description: Every patient received intradermal mixed methylene blue compound injection twice.
Study: NCT00078624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional exercise therapy for knee osteoarthritis
Description: Exercises include stretching, strengthening, and aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee stability training
Description: The addition of agility and perturbation training techniques to the traditional exercise program
Study: NCT03292913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Health Check
Description: Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
Study: NCT02773368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: IDegLira will be given subcutaneously ( s.c., under the skin) once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: IGlar will be given subcutaneously ( s.c., under the skin) once daily.
Study: NCT04342260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Monitoring
Description: The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Monitoring
Description: Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
Study: NCT02743910

Intervention type: OTHER
Intervention: ptDNA
Description: Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.

Intervention type: OTHER
Intervention: Tissue sample
Description: Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
Study: NCT02752763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: %40 diluted Autologous serum
Description: Serum that obtained after centrifugation of blood sample

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
Description: Preservative free artificial tears is a group naming for drops commonly used for drye disease
Study: NCT01646138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ca/04/2009/H1N1 Vero Grown Challenge Virus
Description: The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
Study: NCT00979914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education programme
Description: The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
Study: NCT03292913

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
Study: NCT00803595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir phosphate
Description: CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
Study: NCT04118075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-CY-FK +/-ATG
Description: GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
Study: NCT04083703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interbody cage insertion in lumbar disc prolapse
Description: Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interbody cage insertion in lumbar disc prolapse
Description: Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
Study: NCT03009162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 200 mg, single oral tablet
Study: NCT03785366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VeraCept
Description: VeraCept Intrauterine Device (IUD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ParaGard
Description: ParaGard intrauterine copper contraceptive
Study: NCT03038594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.09% Saline Solution